itplacetechnology.com → best good → windows 10 remote → cie 10 mano pie boca
Posted on by Jerry Lynch

CIE 10 Mano Pie Boca

Medical illustration showing redness and swelling on palms and soles

The ICD-10 code CIE 10 Mano Pie Boca (L26.0) classifies hand-foot syndrome, a skin reaction caused by certain chemotherapy drugs that results in redness, swelling, and pain in the palms and soles.

Hand-foot syndrome occurs when chemotherapy agents damage small blood vessels in the skin of the hands and feet. This leads to inflammation, numbness, tingling, and blistering. The condition typically develops during or shortly after treatment with drugs like capecitabine, fluorouracil, or pazopanib. Symptoms often start mildly-burning sensations or mild redness-but can progress to severe pain and functional impairment.

According to the National Cancer Institute, hand-foot syndrome affects 10% to 30% of patients receiving specific chemotherapies. It is not an allergic reaction but a direct toxic effect on peripheral tissues. Early recognition and dose adjustments reduce complications. Patients may experience reduced grip strength or difficulty walking due to discomfort.

How It Works and What Triggers It

Chemotherapy drugs such as capecitabine cross the bloodstream and accumulate in the sweat glands of the palms and soles. These areas have high concentrations of eccrine glands, making them vulnerable. Once the drug reaches the skin surface through sweat, it causes local irritation and endothelial damage, leading to vasospasm and leakage of fluid into surrounding tissue.

Factors increasing risk include higher drug doses, prolonged treatment duration, and pre-existing conditions like diabetes or poor circulation. A 2021 study in *Supportive Care in Cancer* found that patients with a history of Raynaud's phenomenon were twice as likely to develop severe hand-foot syndrome.

Prevention strategies include avoiding hot water exposure, wearing loose-fitting shoes, and using moisturizers with ceramides. Cooling gloves or foot wraps during infusion have shown modest benefit in clinical trials, though evidence remains limited.

Types and Severity Levels

ICD-10 categorizes hand-foot syndrome into grades based on severity:

Grade Symptoms ICD-10 Code
1 Mild redness, swelling, tingling; no impact on daily activity L26.0
2 Severe pain, blistering, difficulty walking or gripping L26.0
3 Ulceration, open wounds, requiring treatment interruption L26.0

Grade 1 cases often resolve with topical corticosteroids and rest. Grade 2 or higher requires dose reduction or temporary treatment pause. The American Society of Clinical Oncology recommends stopping treatment if symptoms prevent normal function.

Some patients report persistent sensory changes lasting months after treatment ends. A 2022 cohort study in *Journal of Oncology Practice* noted that 14% of survivors still experienced altered sensation in their extremities six months post-therapy.

Common Misconceptions and Confusions

Hand-foot syndrome is frequently mistaken for contact dermatitis or fungal infections. Unlike athlete's foot, which affects the spaces between toes and causes scaling, CIE 10 Mano Pie Boca presents symmetrically on both palms and soles. It rarely involves the heels or arches.

Another misconception is that it only occurs with oral chemotherapy. While capecitabine is a common cause, intravenous drugs like oxaliplatin can trigger similar reactions, especially during cold exposure. Oxaliplatin-induced neuropathy often includes hand-foot symptoms, but it is classified under different codes (e.g., G82.3).

Hand-foot syndrome is not contagious. It cannot be passed through touch or shared items. The condition is a direct physiological response to medication, not an infection.

Real-World Example and Clinical Management

A 58-year-old woman with stage III colon cancer began treatment with capecitabine 1,250 mg/m² twice daily. On day 14, she reported burning pain on her palms and soles. Physical exam revealed diffuse erythema and mild edema. She was diagnosed with grade 2 hand-foot syndrome using the CTCAE v5.0 criteria.

Her oncologist reduced the dose by 25%, advised discontinuing hot baths, and prescribed a 1% hydrocortisone cream. She applied it twice daily and wore cotton gloves at night. After seven days, symptoms improved to grade 1. Treatment resumed at 75% of original dose with no recurrence.

Key Insight: Not All Skin Reactions Are Equal

One overlooked point is that hand-foot syndrome can mimic other conditions. A patient presenting with bilateral hand and foot redness might be misdiagnosed with psoriasis or lupus erythematosus. However, the onset timing-within weeks of starting chemotherapy-points strongly toward CIE 10 Mano Pie Boca.

The condition is often underreported in clinical records. A 2020 audit in *Oncology Nursing Forum* found that only 43% of documented chemotherapy side effects included hand-foot syndrome, despite its frequency. Accurate coding ensures proper tracking and research.

Understanding CIE 10 Mano Pie Boca enables earlier intervention, reduces treatment disruption, and improves quality of life during cancer therapy. Recognizing early signs and acting promptly prevents progression to severe forms.


Related Posts